ood morning, everyone, and welcome to the middle of the week. There’s just a few more days until the rush of meetings and deadlines and paperwork can be put aside for a bit of late-summer relaxation. So, in the meantime, keep plugging away. I’m Rebecca Robbins, and I’m a reporter for STAT, filling in again to bring you a menu of headlines from the world of pharma. Shall we get started?

Teva (TEVA) is looking for partners to help fund development of some of the drug compounds in its pipeline, Reuters informs us. The generic drug giant aims to reduce its debt load by more than $5 billion this year.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.